Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Solid Biosciences (SLDB) Income from Continuing Operations: 2017-2024

Historic Income from Continuing Operations for Solid Biosciences (SLDB) over the last 7 years, with Dec 2024 value amounting to -$38.0 million.

  • Solid Biosciences' Income from Continuing Operations fell 84.64% to -$38.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$120.6 million, marking a year-over-year decrease of 24.19%. This contributed to the annual value of -$120.6 million for FY2024, which is 24.19% down from last year.
  • Latest data reveals that Solid Biosciences reported Income from Continuing Operations of -$38.0 million as of Q4 2024, which was down 15.51% from -$32.9 million recorded in Q3 2024.
  • Over the past 5 years, Solid Biosciences' Income from Continuing Operations peaked at -$19.0 million during Q2 2020, and registered a low of -$38.0 million during Q4 2024.
  • In the last 3 years, Solid Biosciences' Income from Continuing Operations had a median value of -$25.3 million in 2024 and averaged -$27.0 million.
  • Per our database at Business Quant, Solid Biosciences' Income from Continuing Operations surged by 37.62% in 2023 and then crashed by 84.64% in 2024.
  • Quarterly analysis of 4 years shows Solid Biosciences' Income from Continuing Operations stood at -$21.4 million in 2020, then reached -$33.0 million in 2022, then skyrocketed by 37.62% to -$20.6 million in 2023, then plummeted by 84.64% to -$38.0 million in 2024.
  • Its Income from Continuing Operations stands at -$38.0 million for Q4 2024, versus -$32.9 million for Q3 2024 and -$25.3 million for Q2 2024.